Sanofi GCVRZ 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 --
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
今天 01:57
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.
06-24 00:21
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.
06-16 01:15
百济神州聘任62岁Xiaodong Wang（王晓东）为董事，董事会主席John V. Oyler（欧雷强）年薪最高2103万，高级副总裁Chan Lee薪酬最低为897万
6月12日，百济神州公告，聘任Xiaodong Wang（王晓东）先生为公司董事。资料显示，Xiaodong Wang（王晓东），男，美国国籍，博士学位，公司的...
06-12 09:55
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
06-11 21:09
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.
06-05 19:01
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
04-30 01:57
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by strong Dupixent growth.
04-23 23:02
Earnings Scheduled For April 23, 2026
Companies Reporting Before The Bell • Popular (NASDAQ:BPOP) is estimated to rep...
04-23 19:11
